AIMS: The objective of the registry of gastric cancer treatment evaluation (REGATE) study was to evaluate approaches to gastric cancer treatment in different geographical regions. METHODS: REGATE enrolled patients with newly diagnosed gastric cancer at any stage of the disease from the Asia-Pacific region, Europe, the Indian subcontinent, Latin America and North Africa between 2004 and 2008. RESULTS: Among 9965 patients, 69% received surgery, 40% palliative care, 29% adjuvant therapy and 2% neoadjuvant therapy; 15% received no treatment. Combination treatment (mostly surgery/adjuvant) was used in one-third of patients. Overall, 90% received chemotherapy (mostly fluoropyrimidine/platinum combinations but with marked geographical variation) and 21% received radiotherapy. Curative surgery alone was used most frequently for stages 0-II cancers and was employed more often in Europe (55%) and the Asia-Pacific (48%) than in other regions (27-35%). Asia-Pacific and Indian subcontinent patients were more likely to have a distal subtotal gastrectomy and less likely to undergo total gastrectomy than patients in other regions. Lymph node D2 dissection was favored in the Asia-Pacific, Europe and Latin America, whereas D1 dissection was used more in the Indian subcontinent and North Africa. CONCLUSION: These data showing geographical differences in the approaches to gastric cancer treatment may promote the optimization of the management of gastric cancer globally.
AIMS: The objective of the registry of gastric cancer treatment evaluation (REGATE) study was to evaluate approaches to gastric cancer treatment in different geographical regions. METHODS: REGATE enrolled patients with newly diagnosed gastric cancer at any stage of the disease from the Asia-Pacific region, Europe, the Indian subcontinent, Latin America and North Africa between 2004 and 2008. RESULTS: Among 9965 patients, 69% received surgery, 40% palliative care, 29% adjuvant therapy and 2% neoadjuvant therapy; 15% received no treatment. Combination treatment (mostly surgery/adjuvant) was used in one-third of patients. Overall, 90% received chemotherapy (mostly fluoropyrimidine/platinum combinations but with marked geographical variation) and 21% received radiotherapy. Curative surgery alone was used most frequently for stages 0-II cancers and was employed more often in Europe (55%) and the Asia-Pacific (48%) than in other regions (27-35%). Asia-Pacific and Indian subcontinent patients were more likely to have a distal subtotal gastrectomy and less likely to undergo total gastrectomy than patients in other regions. Lymph node D2 dissection was favored in the Asia-Pacific, Europe and Latin America, whereas D1 dissection was used more in the Indian subcontinent and North Africa. CONCLUSION: These data showing geographical differences in the approaches to gastric cancer treatment may promote the optimization of the management of gastric cancer globally.
Authors: Jin Won Kim; Jong Gwang Kim; Byung Woog Kang; Ik-Joo Chung; Young Seon Hong; Tae-You Kim; Hong Suk Song; Kyung Hee Lee; Dae Young Zang; Yoon Ho Ko; Eun-Kee Song; Jin Ho Baek; Dong-Hoe Koo; So Yeon Oh; Hana Cho; Keun-Wook Lee Journal: Cancer Res Treat Date: 2018-10-19 Impact factor: 4.679
Authors: Mariana Serrano; Jhajaira M Araujo; Cristian Pacheco; Jackeline Macetas; Mariella A Blum; Alfredo Carrato; Eloy Ruiz; Francisco Berrospi; Carlos Luque; Ivan Chavez; Eduardo Payet; Luis Taxa; Paola Montenegro Journal: Ecancermedicalscience Date: 2022-05-12
Authors: Gebra Cuyun Carter; Anna Kaltenboeck; Jasmina Ivanova; Astra M Liepa; Alexandra San Roman; Maria Koh; Narayan Rajan; Rebecca Cheng; Howard G Birnbaum; Jong Seok Kim; Yung-Jue Bang Journal: Cancer Res Treat Date: 2016-09-12 Impact factor: 4.679
Authors: Sergei A Tjulandin; Alexey A Tryakin; Natalia S Besova; Evgeniya Sholokhova; Jasmina I Ivanova; Wendy Y Cheng; Luke M Schmerold; Philippe Thompson-Leduc; Diego Novick Journal: J Drug Assess Date: 2019-09-17